The
Introduction
The association of Graves' disease with neutropenia was first described by Kocher (1) in 1908, and subsequently confirmed (2) . Other groups, studying patients with autoimmune neutropenia, have observed a number of individuals with concurrent or prior thyroid disease. The coexistence of both neutropenia and Graves' disease in some patients led us to study systematically a group of patients with Graves' disease for the presence of antineutrophil autoantibodies. Furthermore, we questioned whether the autoantibodies directed against thyroid thyrotropin (TSH)' receptors may cross-react with thyrotropinbinding moieties on neutrophils. To investigate this hypothesis, we studied the binding of thyrotropin to human neutrophils 1. Abbreviations used in this paper: bTSH, bovine thyrotropin; hTSH, human thyrotropin; KRP, Krebs-Ringer-phosphate medium; TSH, thyrotropin; TSI, thyroid-stimulating immunoglobulins. and the interactions in vitro of thyrotropin, antineutrophil autoantibodies, and neutrophils.
Methods
Patients. Sera and citrated whole blood were obtained from patients with Graves' disease and normal volunteers after informed consent. 22 patients were studied. There were 18 females and 4 males, with an age range of 23-74 yr. Their therapy and clinical status is presented in Table I . Patients were classified as having Graves' disease on the basis of the presence of diffuse goiter, exophthalmos, and a current or documented history of hyperthyroidism. Hyperthyroidism was defined on the basis of classical clinical symptoms, elevated serum thyroxine and triiodothyronine concentrations, and undetectable serum TSH levels. Patients were considered euthyroid by an absence of clinical symptoms of hyperthyroidism or hypothyroidism with normal serum thyroxine and triiodothyronine levels.
Neutrophils were purified by sedimentation of citrated blood with dextran (3). The leukocyte-rich supernatants were then centrifuged on Ficoll-sodium diatrizoate gradients, and erythrocyte contamination of the pellets was removed by hypotonic lysis.
IgG was purified by ammonium sulfate precipitation followed by ion exchange chromatography on diethylaminoethyl cellulose (4) . Antineutrophil antibodies were assessed by two methods. The cell:cell recognition assay was used to detect antineutrophil antibody opsonic activity in serum as previously described (3, 5 To assess whether deiodination or degradation of hormone occurred, 5 X 101 neutrophils were incubated with '251-hTSH for various times at both 22°and 370C. At the completion of incubation, the cells were pelleted by centrifugation at 12,000 g for I min, and the supernatant was assayed for immunoprecipitability of radioactivity, using rabbit anti-hTSH serum as noted above. This was compared with immunoprecipitability of preincubation samples of labeled hTSH.
Reversibility of binding was investigated by incubating cells with '5I-hTSH as described above, subsequently adding excess unlabeled hormone to the incubation, and then determining residual counts bound to cells.
Results
Antineutrophil antibodies. Using the opsonic method to assay serum against homologous neutrophils, 6 of 11 Graves' patients had antibodies. Using the staphylococcal assay for the same purpose, the sera of 10 of 20 patients were positive. When we studied the autologous neutrophils of eight patients by the staphylococcal slide test, seven of them were found to have cell-bound antibodies, including two in whom the sera were negative for binding of antineutrophil IgG to homologous cells. Antibodies to lymphocytes were not found. As shown in Table I , antibodies were detected even in patients with normal neutrophil counts. Neutropenia (<1,800/mm3) was observed in two patients off treatment as well as in two patients who were possibly neutropenic because of reaction to propylthiouracil or methimazole.
Inhibition of antineutrophil opsonic antibody activity by TSH. When bTSH was added to test cell incubations, the opsonic activity of these antibodies was inhibited in a dosedependent fashion (Fig. 1) . bTSH did not, however, inhibit the opsonizing activity of serum from two patients with 400 Cl)l 0It tK 0t immune neutropenia who had no history of, or evidence of, thyroid disease (Fig. 1) .
Binding of hTSH to neutrophils. hTSH was noted to bind rapidly, stably, and reversibly (Fig. 2) to human neutrophils. Specific binding (as defined above) varied between 2.5 and 16% of the added counts. Nonspecific binding was always <20% of the specific binding and generally much lower (in many experiments, there was no nonspecific binding in excess of the cell-free control filter blanks). The effects of pH on this system are also illustrated in Fig. 2. As noted by others (10,  1 1) , specific binding to TSH is greatest at low pH, intermediate in the physiologic range, and lowest at alkaline pH. Effects of temperature are shown in Table II Fig. 3 . Unlabeled human TSH was much more efficient at competing with labeled human TSH for binding to neutrophils than was unlabeled purified bTSH. Neither follicle-stimulating hormone nor luteinizing hormone had competing activity.
Discussion
The major points in this study are (a) patients with Graves' disease frequently have antineutrophil autoantibodies, (b) TSH inhibits the opsonic activity of these antibodies, and (c) TSH binds to neutrophils rapidly and reversibly. TSH binding has been described with a variety of tissues (10, 11, (14) (15) (16) . Published data on the binding characteristics vary widely, depending on both the methods used and the species source of TSH and cell (or membrane) preparations. Reports from other laboratories agree with our observations of certain important features, such as the rapid time course of binding (14) and pH dependence (10, 1 1). Also, receptors for porcine TSH have been described on human neutrophils (16) .
Whether these neutrophil binding sites represent biologically important "physiologic receptors" is not certain, but some studies show that TSH may initiate neutrophil cyclic AMP production and may be relevant in neutrophil function (17) .
Hyperthyroidism in Graves' disease is thought to be due to autoantibodies directed against TSH receptors on thyroid cells (18) (19) (20) (21) (22) (23) (24) (21, 22) . Since the antineutrophil antibodies described here behave in a manner similar to the thyroid thyrotropin displacing immunoglobulins, it is possible that these two types of autoantibodies are actually the same, i.e., directed against the same or similar antigens expressed on more than one tissue.
The finding of circulating antineutrophil antibodies in 50-55% of our patients raises several questions, including (a) Why were so few of these individuals neutropenic? and (b) If these antibodies are related to those presumed pathogenic in Graves' disease, why were they not found in a higher fraction of patients? At least two possible explanations exist for the first question. First, it is possible that some of the antibodies may not, in Vivo, alter the survival of the neutrophils against which they are directed, or, second, in cases where cell lifespan is shortened, increased marrow production might compensate (similar to the compensated hemolytic state of some erythrocyte disorders). The second question is more complex, but some of our data may help approach its answer. While serum antibodies against homologous cells were not found in almost half the patients, cell-bound IgG antibody was observed on autologous cells of seven of eight patients so studied. These findings are similar to the results of Coombs' antiglobulin test in autoimmune hemolytic anemia. While cell-bound antibody may be found in almost all cases (i.e., the direct antiglobulin test), the indirect test for serum antibody can be negative from 20 to 65% of the time, depending on the method of erythrocyte preparation (25) . This analogy might also explain some of the false negative tests for TSI or thyrotropin displacing activity that can be observed in Graves' patients (26) . Until recently (21, 22) , these negative results occurred often enough to have cast doubt on the model of Graves' disease as an autoimmune process with antibodies directed against TSH receptors. However, it seems reasonable to postulate, on the basis of what is known about autoimmune hemolytic anemia and the neutrophil data shown here, that in some cases of Graves' disease, most all of the TSI or thyrotropin displacing activity could be cell-bound (either on thyroid or other cells), and that serum levels might be below limits of detection.
